Apnimed Q3 2026 Results: Net Loss of $29.5M, Loss Widens
Apnimed, Inc. is a late-stage clinical pharmaceutical company focused on its lead product candidate, Oxnimbi, which has completed Phase 3 clinical trials. The company reports significant operating losses since inception and anticipates requiring substantial additional funding to support its commercialization efforts and regulatory approval processes.
- Key figure
- Net loss $29.5M